Radiation Therapy and Simultaneous Chemotherapy for Recurrent Cervical Carcinoma

Windschall, Andrea; Ott, Oliver J.; Sauer, Rolf; Strnad, Vratislav

doi:10.1007/s00066-005-1340-8

Cited by 31 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin-based RCT has been used for various tumor entities [3,7,13,16,28]. In esophageal cancer treatment, simultaneous RCT with cisplatin/5-fluorouracil (5-FU) appeared superior to RT alone, which was also demonstrated by the meta-analysis of the Cochrane Work Group [6,29].…”

Section: Introductionmentioning

confidence: 81%

Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 81%

Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Concurrent RCT is now used in a variety of different tumors [9,10,14]; but how can this treatment benefit patients with comorbid conditions? Simultaneous RCT resulted in partial or complete remission in 74% of our patients.…”

Section: Discussionmentioning

confidence: 99%

6-Year Experience of Concurrent Radiochemotherapy with Vinorelbine Plus a Platinum Compound in Multimorbid or Aged Patients with Inoperable Non-Small Cell Lung Cancer

et al. 2007

View full text Add to dashboard Cite

After including a larger group of patients than in 2003 and following the patients for several years, the authors determine that concurrent RCT consisting of vinorelbine plus a platinum compound and conventional fractionated radiotherapy can be carried out with manageable toxicity, even in this negatively selected population of patients. Their survival rates were comparable to those achieved in other studies with simultaneous RCT.

show abstract

“…Irradiation or concurrent cisplatin-based chemo-radiation is the treatment of choice for patients with pelvic recurrence after radical hysterectomy alone (3,4,(11)(12)(13)(14)(15)(16)(17)(18). However, the safe delivery of high doses of radiotherapy is much more difficult in this clinical setting compared with primary radiotherapy, since brachytherapy options are limited to treatment of the vaginal vault alone and since the presence of post-surgical adhesions increases the radiation dose to the bowel (19,20).…”

Section: Central or Lateral Pelvic Recurrence In Patients Primarily Tmentioning

confidence: 99%

Treatment options in recurrent cervical cancer (Review)

Gadducci¹,

Tana²,

Cosio³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. the management of recurrent cervical cancer depends mainly on previous treatment and on the site and extent of recurrence. concurrent cisplatin-based chemoradiation is the treatment of choice for patients with pelvic failure after radical hysterectomy alone. However, the safe delivery of high doses of radiotherapy is much more difficult in this clinical setting compared with primary radiotherapy. Pelvic exenteration usually represents the only therapeutic approach with curative intent for women with central pelvic relapse who have previously received irradiation. In a recent series, the 5-year overall survival and operative mortality after pelvic exenteration ranged from 21 to 61% and from 1 to 10%, respectively. Free surgical margins, negative lymph nodes, small tumour size and long disease-free interval were associated with a more favourable prognosis. currently, pelvic reconstructive procedures (continent urinary conduit, low colorectal anastomosis, vaginal reconstruction with myocutaneous flaps) are strongly recommended after exenteration. concurrent cisplatin-based chemo-radiation is the treatment of choice for isolated para-aortic lymph node failure, with satisfactory chances of a cure in asymptomatic patients. chemotherapy is administered with palliative intent to women with distant or loco-regional recurrences not amenable by surgery or radiotherapy. cisplatin is the most widely used drug, with a response rate of 17-38% and a median overall survival of 6.1-7.1 months. cisplatin-based combination chemotherapy achieves higher response rates (22-68%) when compared with single-agent cisplatin, but median overall survival is usually less than one year. In a recent gynecologic Oncology Group (GOG) trial the combination topotecan + cisplatin obtained a significantly longer overall survival than single-agent cisplatin in patients with metastatic or recurrent or persistent cervical cancer. A subsequent gog study showed a trend in terms of longer overall survival and better quality of life for the doublet cisplatin + paclitaxel vs. the doublets cisplatin + topotecan, cisplatin + vinorelbine, and cisplatin + gemcitabine. Molecularly targeted therapy may represent a novel therapeutic tool, but its use alone or in combination with chemotherapy is still investigational.

show abstract

Radiation Therapy and Simultaneous Chemotherapy for Recurrent Cervical Carcinoma

Abstract: Radiation therapy with simultaneous chemotherapy for recurrences of cervical cancer is an effective treatment with acceptable toxicity.

Cited by 31 publications

References 25 publications

Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*

Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*

6-Year Experience of Concurrent Radiochemotherapy with Vinorelbine Plus a Platinum Compound in Multimorbid or Aged Patients with Inoperable Non-Small Cell Lung Cancer

Treatment options in recurrent cervical cancer (Review)

Contact Info

Product

Resources

About